The transdermal contraceptive patch: an updated review of the literature.
Clin Obstet Gynecol
; 50(4): 918-26, 2007 Dec.
Article
em En
| MEDLINE
| ID: mdl-17982334
ABSTRACT
The transdermal contraceptive patch which contains ethinyl estradiol and norelgestromin has an efficacy similar to current oral contraceptives (OCs). The major advantages include transdermal application and maintenance of adequate hormonal levels for at least 7 days. Side effects are similar to OC except for breast tenderness in the first 2 months of use and skin irritation at the application site. Although concern has been raised about a possible increased risk of venous thromboembolism, current available data comparing the patch to a norgestimate-containing OC ranges from no increase in risk to a 2.4-fold increase.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Peso Corporal
/
Anticoncepcionais Femininos
/
Ciclo Menstrual
Tipo de estudo:
Etiology_studies
/
Risk_factors_studies
Limite:
Adolescent
/
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Clin Obstet Gynecol
Ano de publicação:
2007
Tipo de documento:
Article
País de afiliação:
Estados Unidos